← Eichor
Study identifier: NCT07243379 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia

Condition: Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia · Multicenter Observational Study  ·  Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

PhasePhase 4
Planned participants495
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.

This description comes directly from the study's public registry record.

Talk to the study team

Suxia Luo  ·  18638553211  ·  luosxrm@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Henan Cancer Hospital, Affiliated to Zhengzhou UniversityZhengzhou, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07243379